No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by surging demand for its diabetes drug Mounjaro and weight-loss treatment Zepbound.
Eli Lilly said revenues jumped 54% year-on-year to $17.6bn, with US sales up 45% to $11.3bn, driven by a 60% increase in prescription volumes. Net income rose to $5.58bn, or $6.21 per share, from $970m a year earlier, while adjusted earnings came in at $7.02 per share.
Mounjaro generated $6.52bn in revenue, up 109% and well ahead of forecasts, while Zepbound rose 184% to $3.59bn, slightly beating expectations.
Eli Lilly also raised its full-year guidance, with the firm now expecting revenue to be between $63bn and $63.5bn and adjusted profits to be $23-$23.70 per share. It also noted that its outlook reflects current US tariffs, but excluded potential new levies on imported pharmaceuticals.
As of 1430 GMT, Eli Lilly shares were up 0.85% at $820.45 each.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.